Tiverton Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Tiverton Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.1M	Buy	51,385 +48,585	+1,735%	+$1.34M	0.04%	280
2019 Q2	$76K	Buy	+2,800	New	+$76.3K	﹤0.01%	643

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tiverton Asset Management's BBIO Position: Q3 2019 in Review

Tiverton Asset Management increased its BridgeBio Pharma (BBIO) stake by 1,735% in Q3 2019, buying an estimated $1.34M and bringing the position to 51,385 shares worth $1.1M. The position accounts for 0.04% of the portfolio, ranked #280.

Tiverton Asset Management first reported a position in BBIO in Q2 2019 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold BBIO as of Q3 2019.

Tiverton Asset Management held 51,385 shares of BridgeBio Pharma worth $1.1M as of Q3 2019.
Tiverton Asset Management bought 48,585 BridgeBio Pharma shares in Q3 2019, an estimated $1.34M.
BridgeBio Pharma made up 0.04% of Tiverton Asset Management's portfolio in Q3 2019, its #280 holding.
Tiverton Asset Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 2 quarters since.
75 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.